PER® New York Lung Cancer Symposium | Conference

Dr Borghaei on Determining Treatments Utilizing Biomarker Testing in NSCLC

November 14th 2023

Hossein Borghaei, DO, MS, discusses the importance of determining the most suitable treatment for patients with non–small cell lung cancer through the use of biomarker testing.

Dr Liu on the Benefits of Biomarker Testing in NSCLC

November 14th 2023

Stephen V. Liu, MD, discusses the benefits of conducting biomarker testing for patients with advanced non–small cell lung cancer and highlights the importance of waiting for the results before selecting a targeted treatment.

Interim Management Strategies Could Aid Patients With Advanced NSCLC Awaiting Biomarker Test Results

November 13th 2023

Stephen V. Liu, MD, discusses strategies for treatment and disease management for patients with advanced non–small cell lung cancer who are awaiting biomarker test results.

Emerging Data Highlight Potential for Frontline Combinations in EGFR+ NSCLC

November 13th 2023

Ongoing research evaluating combination therapies for the frontline treatment of patients with EGFR-mutated non–small cell lung cancer could help improve survival outcomes for this patient population.

Case Study Highlights Uncommon Skin Rash as Possible Sign of Lung Cancer Recurrence

November 13th 2023

Nicholas C. Rohs, MD, delves into the details of the case study a patient who had a lung cancer relapse detected following a referral to a dermatologist due to pityriasis rubra pilaris.

Dr Rohs on Pityriasis Rubra Pilaris as an Early Signal of Lung Cancer Recurrence

November 11th 2023

Nicholas C. Rohs, MD, discusses a case study that he presented during the Interesting Cases session at the 18th Annual New York Lung Cancers Symposium®.

Dr Levy on Onco-Directed ADCs in NSCLC

November 11th 2023

Benjamin Philip Levy, MD, discusses antibody-drug conjugates under investigation in patients with non–small cell lung cancer.

Early Use of ctDNA May Accelerate Time to Treatment and Improve Survival in NSCLC

November 11th 2023

While there are considerable barriers to incorporating comprehensive genotyping, the use of circulating tumor DNA offers an improvement in molecular testing—and doing so earlier can accelerate the time to treatment and improve survival for patients with lung cancer.

IO Combos Yield OS Advantage Vs Chemo Alone in Stage IV PD-L1–Negative NSCLC

November 11th 2023

As treatments for patients with stage IV non–small cell lung cancer continue to evolve, patients with PD-L1–negative disease represent a unique cohort and chemotherapy/immunotherapy or immunotherapy doublet regimens appear to be effective.

Management of irAEs in Cancer Care Requires Novel Strategies Beyond Steroids

November 11th 2023

Although the emergence of immunotherapy have created additional treatment options for patients with various types of cancer, these agents are associated with significant toxicities and immune-related adverse effects.

Dr. Halmos on Trastuzumab Deruxtecan in NSCLC

November 14th 2022

Balazs Halmos, MD, discusses the importance of testing for HER2 mutations and exon 20 insertions, which are emerging new targets in non–small cell lung cancer, and how fam-trastuzumab deruxtecan-nxki meets needs for patients with HER2-mutant disease.

Dr. Kris on Immunotherapy in NSCLC Without Driver Mutations

November 14th 2022

Mark G. Kris, MD, discusses the role of immunotherapy in patients with non–small cell lung cancer without driver mutations.

Checkpoint Inhibitor Challenges Warrant Consideration for a Targeted Approach in NSCLC

November 14th 2022

In treating patients with locally advanced non–small cell lung cancer, one must consider multiple factors when deciding whether to treat them with immunotherapy or a targeted approach, even though the optimal treatment sequence has yet to be definitively established.

Osimertinib Remains the Preferred Frontline Choice for EGFR-Mutated NSCLC

November 14th 2022

Osimertinib remains the preferred first-line therapy for patients with EGFR-mutated non–small cell lung cancer. However, for those with classic EGFR mutations, the day is fast approaching when physicians will add chemotherapy to first-line treatment with the EGFR TKI based on ctDNA results.

Targeting the ‘New Kids on the Block’ in NSCLC: EGFR Exon 20 and MET Exon 14 Skipping Mutations

November 14th 2022

Investigators are harnessing comprehensive molecular profiling to detect new targets, optimize existing treatment regimens, and develop novel therapies for patients with EGFR and MET exon 20–insertion positive non–small cell lung cancer.

Dr. Saxena on a Challenging Case of NSCLC

November 8th 2021

Ashish Saxena, MD, PhD, discusses a challenging case of a patient with non–small cell lung cancer.

Dr. Zauderer on the Importance of Optimizing Care in Mesothelioma

November 8th 2021

Marjorie G. Zauderer, MD, discusses the importance of optimizing care for patients with mesothelioma.

Overcoming Mechanisms of Resistance Remains at the Forefront for EGFR-Mutant NSCLC

November 8th 2021

Although next-generation TKIs have helped to overcome resistance in EGFR-mutated non–small cell lung cancer, a more complete understanding of resistance mechanisms may lead to the ability to overcome resistance to the next generation of these drugs.

KRAS G12C Inhibitors Enter the Spotlight in NSCLC

November 8th 2021

The era of direct inhibitors to treat KRAS G12C-mutated non-small cell lung cancer has arrived in the clinic.

Future of Lung Cancer Treatment Looks Bright With Emerging Technologies, Novel Discoveries

November 8th 2021

Mark G. Kris, MD, discusses recent progress in non–small cell lung cancer and small cell lung cancer, efforts being made to address unmet needs in these paradigms, and ongoing research that is generating excitement.